QLGN News and Press, Qualigen Therapeutics Inc. From 08/15/23

2023-08-15 09:10:45 ET Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q2 GAAP EPS of -$0.69. Revenue of $1.62M (+13.3% Y/Y). Sales and marketing expenses were approximately $0.2 million for the quarter ended June 30, 2023, a decrease of $0.1 million or 45%, co...

Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack ® diagnostics business for approximately $5 mi llion in all cash transaction to support advancement of thera...

2023-08-01 10:24:36 ET The US FDA has cleared an Investigational New Drug ( IND ) application from Qualigen ( NASDAQ: QLGN ) to conduct a phase 1 trial of QN-302 for solid tumors. The trial of the G-Quadruplex (G4)-selective transcription inhibitor will begin in the second...

Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and d emonstrates leadership in G4-targeting therapies for areas of high unmet need in oncology CARLSBAD, Calif., Aug. 01, ...

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a therapeutics company focu...

2023-07-18 13:23:21 ET Gainers: Evelo Biosciences ( EVLO ) +34% . Biophytis S.A. ( BPTS ) +30% . The Singing Machine Company ( MICS ) +29% . Hyperfine ( HYPR ) +31% . Advanced Emissions Solutions ( ADES ) +27% . Innodata ( ...

Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds CARLSBAD, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pe...

2023-05-16 09:02:30 ET Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q1 GAAP EPS of -$0.78. Revenue of $1.61M (+123.6% Y/Y). For further details see: Qualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61M

Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Design...

2023-05-02 17:14:48 ET Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q4 GAAP EPS of -$4.85 misses by $3.60 . Revenue of $5M (-12.3% Y/Y) beats by $3.43M . For further details see: Qualigen Therapeutics GAAP EPS of -$4.85 misses by $3.60, revenue o...